US regulators have cleared NTS231 for clinical testing, giving the Shanghai biotech Nutshell Therapeutics its first American trial. The molecule belongs to a class known as molecular glues: small compounds that make a target protein easier for the cell’s own disposal machinery to grab and break down.
Treatment resistance in solid tumors often runs through a single pathway. NRF2 helps cancer cells survive oxidative stress, and that is a large part of why tumors return after therapy. Drugmakers have found the protein hard to hit with conventional chemistry, which is why glues and degraders have become the route of choice. Nutshell built its candidate with an internal design loop it calls ALLOSTAR, which runs computation, medicinal chemistry and bench work together.
Molecular glues are a crowded bet. Several compounds in the class have drawn large pharma partnerships over the past year, and a candidate is judged by whether the glue holds inside patients rather than on a bench. Trials will need to show degradation in tumors and establish which cancer types carry the right biology.
The clearance moves a preclinical asset into the phase where most programs fail. It also hands Nutshell a US data package, which matters for any licensing conversation.
